In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
News|Videos|June 3, 2026
6 Gastroenterology Headlines You Missed in May 2026
Author(s)Abigail Brooks, MA
Fact checked by: Alex Hillenbrand
Catch up on GI regulatory actions and top headlines from DDW in this May month in review.
Advertisement
Advertisement
May was a busy month in gastroenterology, marked by regulatory approvals, practice-changing data presentations at Digestive Disease Week (DDW) 2026, and continued advances in the management of
Related to this article
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.
George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Advertisement
Advertisement